178 related articles for article (PubMed ID: 37871574)
1. Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1-mediated immune suppression during GVHD.
Wang Y; He S; Calendo G; Bui T; Tian Y; Lee CY; Zhou Y; Zhao X; Abraham C; Mo W; Chen M; Sanders-Braggs R; Madzo J; Issa JP; Hexner EO; Wiest DL; Reshef R; Xue HH; Zhang Y
Blood; 2024 Jan; 143(2):166-177. PubMed ID: 37871574
[TBL] [Abstract][Full Text] [Related]
2. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
Fujiwara H; Maeda Y; Kobayashi K; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Chen L; Azuma M; Yagita H; Tanimoto M
J Immunol; 2014 Sep; 193(5):2565-73. PubMed ID: 25080485
[TBL] [Abstract][Full Text] [Related]
3. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
Kato K; Cui S; Kuick R; Mineishi S; Hexner E; Ferrara JL; Emerson SG; Zhang Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):751-71. PubMed ID: 20116439
[TBL] [Abstract][Full Text] [Related]
4. Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease.
Zhao F; Zhang Y; Wang H; Jin M; He S; Shi Y; Guo Y; Zhang Y
Blood; 2011 Feb; 117(5):1723-33. PubMed ID: 21119110
[TBL] [Abstract][Full Text] [Related]
5. Donor T cell STAT3 deficiency enables tissue PD-L1-dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity.
Li Q; Wang X; Song Q; Yang S; Wu X; Yang D; Marié IJ; Qin H; Zheng M; Nasri U; Kong X; Wang B; Lizhar E; Cassady K; Tompkins J; Levy D; Martin PJ; Zhang X; Zeng D
J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526084
[TBL] [Abstract][Full Text] [Related]
6. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
9. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
[TBL] [Abstract][Full Text] [Related]
10. CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells.
Liu K; Anthony BA; Yearsly MM; Hamadani M; Gaughan A; Wang JJ; Devine SM; Hadley GA
PLoS One; 2011; 6(7):e21968. PubMed ID: 21779359
[TBL] [Abstract][Full Text] [Related]
11. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
12. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.
Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D
Front Immunol; 2022; 13():907673. PubMed ID: 35677056
[TBL] [Abstract][Full Text] [Related]
13. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
[TBL] [Abstract][Full Text] [Related]
15. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
[TBL] [Abstract][Full Text] [Related]
17. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model.
Neidemire-Colley L; Khanal S; Braunreiter KM; Gao Y; Kumar R; Snyder KJ; Weber MA; Surana S; Toirov O; Karunasiri M; Duszynski ME; Chi M; Malik P; Kalyan S; Chan WK; Naeimi Kararoudi M; Choe HK; Garzon R; Ranganathan P
Blood Adv; 2024 Feb; 8(4):947-958. PubMed ID: 38181781
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.
Okiyama N; Katz SI
J Autoimmun; 2014 Sep; 53():1-9. PubMed ID: 25047812
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
Ni X; Song Q; Cassady K; Deng R; Jin H; Zhang M; Dong H; Forman S; Martin PJ; Chen YZ; Wang J; Zeng D
J Clin Invest; 2017 May; 127(5):1960-1977. PubMed ID: 28414296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]